Aarti Drugs Announces 41st AGM on September 26, 2026
Aarti Drugs Ltd has announced its 41st Annual General Meeting (AGM) to be held on Saturday, September 26, 2026, at 11:00 a.m. (IST) through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company will also share its Annual Report for the Financial Year 2025-26 with shareholders electronically. The report highlights significant progress in FY 2025-26, including the commencement of commercial production at the Sayakha facility, increased Salicylic Acid production at Tarapur, and expanded regulatory approvals from USFDA, UK MHRA, and EU GMP, contributing to 73% of revenues. Investments in manufacturing, backward integration, and a record-low debt-to-equity ratio are noted as strengthening the company's platform for future growth.
Key Highlights
- AGM scheduled for September 26, 2026, via VC/OAVM.
- Annual Report for FY 2025-26 released with AGM notice.
- Sayakha facility commenced production; Salicylic Acid output increased.
- USFDA, UK MHRA, EU GMP approvals enhance regulated market access.
- Record-low debt-to-equity ratio reflects financial discipline.
Price Impact
More from AARTIDRUGS